Search results
Results from the WOW.Com Content Network
Ranitidine, a heartburn medicine sold under the brand name Zantac among others, was pulled from shelves in 2019, [1] following disclosure [2] of potential carcinogenic effects, [3] [4] which its manufacturers were accused of "engaging in a decades-long scheme to conceal." [5]
For premium support please call: 800-290-4726 more ways to reach us
Ranitidine, previously sold under the brand name Zantac [a] among others, is a medication used to decrease stomach acid production. [12] It was commonly used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. [12] It can be given by mouth, injection into a muscle, or injection into a vein.
In 2020, the U.S. Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after NDMA was found in samples of the drug.
The French pharmaceutical company Sanofi says it has reached an agreement to resolve 4,000 cases in the U.S., in which plaintiffs are linking the discontinued heartburn drug Zantac — and its ...
Zantac can refer to either of two different H 2 antagonists used to reduce gastric acid secretion: Ranitidine , prior to its 2020 withdrawal from the market Famotidine , following the withdrawal of ranitidine
The U.S. Food and Drug Administration (FDA) in 2020 pulled Zantac and its generic versions off the market, triggering a wave of lawsuits. The drug, approved over four decades ago, was the world's ...
Zantac commanded a premium over generic ranitidine drugs. Glaxo Group owned the ranitidine patent and would have owned it even if the appellant had been in an arm's length relationship. Without the License Agreement, the appellant would not have been in a position to use the ranitidine patent and the Zantac trademark.